title: Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors.
abstract: OBJECTIVE
  To assess fear of progression (FoP) in outpatients with chronic myeloid leukemia (CML) on oral tyrosine kinase inhibitors (TKIs).
  
  
  METHODS
  Prospective and descriptive.
  
  
  METHODS
  A university-based outpatient cancer clinic in Wuerzburg, Germany.
  
  
  METHODS
  37 outpatients with CML on oral TKIs.  .
  
  
  METHODS
  FoP was assessed with a questionnaire. Clinical data were extracted from the medical charts. .
  
  
  METHODS
  Frequency and contents of FoP.
  
  
  RESULTS
  Sum scores and levels of FoP in the sample population (N = 37) were as high as in cancer populations with more unfavorable life expectancies. Regarding single items, fear that medication may harm the body was most prevalent, regardless of group affiliation. The actual fear of disease progression was only ranked sixth out of 12 items for the total sample and was ranked second by the second-generation TKI group.
  
  
  CONCLUSIONS
  In a sample of outpatients with CML, FoP was frequent and most often generated by fears of treatment side effects.
  
  
  CONCLUSIONS
  Nurses should be vigilant about FoP in this population. Established questionnaires may help to identify and evaluate this frequent source of distress. Specific communication could reveal unmet informational needs and may help to initiate interventions. Additional studies are needed to confirm the numbers in a larger cohort of patients, to examine the prevalence during the course of disease, to search for potential influences on the outcome (i.e., via adherence), and to extract the best interventions.
authors.affiliation: University of Wuerzburg.
authors.forename: Jochen
authors.initials: J
authors.lastname: Hefner
authors.forename: Eva-Johanna
authors.initials: EJ
authors.lastname: Csef
authors.affiliation: University of Wuerzburg.
authors.forename: Volker
authors.initials: V
authors.lastname: Kunzmann
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D005239:Fear; D005858:Germany; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D055118:Medication Adherence / Q000523:psychology*; D010045:Outpatients / Q000523:psychology*; D011446:Prospective Studies; D011505:Protein-Tyrosine Kinases / Q000627:therapeutic use*; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases
keywords: anxiety; chronic myeloid leukemia; distress; fear; imatinib